<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254526</url>
  </required_header>
  <id_info>
    <org_study_id>PIM4880g</org_study_id>
    <secondary_id>GO00882</secondary_id>
    <nct_id>NCT01254526</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety,
      tolerability, and pharmacokinetics of GDC-0980 administered with taxane-based chemotherapy
      regimens utilized in patients with locally recurrent or metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Through Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Through study completion, up to 1 year, or early discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of GDC-0980, paclitaxel and bevacizumab (including total exposure, maximum and minimum plasma concentration, time to maximum observed plasma concentration, plasma half-life)</measure>
    <time_frame>Through Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Assessed at periodic intervals until study completion, up to 1 year, or early discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Assessed at periodic intervals until study completion, up to 1 year, or early discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Assessed at periodic intervals until study completion, up to 1 year, or early discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0980</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally recurrent or metastatic breast cancer, not amenable to resection with curative
             intent

          -  For Arm C: Overexpression of HER2

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Adequate hematologic and organ function

          -  Evaluable or measurable disease per RECIST (Response Evaluable Criteria in Solid
             Tumors)

          -  Female patients of childbearing potential must use an acceptable method of
             contraception to prevent pregnancy and to continue its use for the duration of the
             study

        Exclusion Criteria:

          -  Prior anti-cancer therapy of more than two regimens of systemic cytotoxic chemotherapy
             for advanced or metastatic breast cancer

          -  Prior anti-cancer therapy (e.g., chemotherapy, biologic therapy, or hormonal therapy)
             within a specified timeframe of the first dose of study treatment

          -  History of Type 1 or Type 2 diabetes requiring regular medication

          -  History of clinically significant cardiac or pulmonary dysfunction

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Any condition requiring full-dose anticoagulants

          -  Leptomeningeal disease as a manifestation of cancer

          -  Active infection requiring IV antibiotics

          -  Active autoimmune disease that is not controlled by non-steroidal anti-inflammatory
             drugs, inhaled steroids, or the equivalent of &lt;= 10 mg/day of prednisone

          -  Known clinically significant history of liver disease, including active viral,
             alcoholic, or other hepatitis, or cirrhosis

          -  Known HIV infection

          -  Known untreated or active CNS metastases

          -  Pregnancy, lactation, or breastfeeding

          -  Major surgical procedure, open biopsy, or significant traumatic injury within a within
             a specified timeframe of the first dose of study treatment

        For Arm B:

          -  Uncontrolled hypertension, complication from hypertension, myocardial infarctions,
             unstable angina, vascular disease or stroke within a specified timeframe of the first
             dose of study treatment

          -  Evidence of bleeding diathesis or significant coagulopathy including hemoptysis within
             a specified timeframe of the first dose of study treatment

          -  History of abdominal conditions (e.g., fistula, perforation, obstruction) that would
             preclude use of bevacizumab

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Proteinuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Lauchle, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

